Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like Takeda Becomes the Latest to Notch an Alzheimer's Failure Under Its Belt January 24, 2018 Celgene Stocks Up on More Juno Stock After Failed Flagship Drug Trial March 28, 2017 Massachusetts' Selecta Banks $50 Million June 25, 2017
